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Abstract 
Lysosome function is essential in cellular 
homeostasis. In addition to its recycling role, the 
lysosome has recently been recognised as a 
cellular signalling hub. We have shown in 
mammary epithelial cells, both in vivo and in 
vitro, that signal transducer and activator of 
transcription 3 (Stat3) modulates lysosome 
biogenesis and can promote the release of 
lysosomal proteases that culminates in cell death. 
To further investigate the impact of Stat3 on 
lysosomal function, we have conducted a 
proteomic screen of changes in lysosomal 
membrane protein components induced by Stat3 
using an iron nanoparticle enrichment strategy. 
Our results show that Stat3 activation not only 
elevates the levels of known membrane proteins 
but results in the appearance of unexpected 
factors, including cell surface proteins such as 
annexins and flotillins. These data suggest that 
Stat3 may co-ordinately regulate endocytosis, 
intracellular trafficking and lysosome biogenesis 
to drive lysosomal-mediated cell death in 
mammary epithelial cells. The methodologies 
described in this study also provide significant 
improvements to current techniques used for the 
purification and analysis of the lysosomal 
proteome. 
 
 
 
 
Introduction 
Lysosomes are intracellular organelles 
that were first described by Christian de Duve 
over half a century ago, so-named from the Greek 
words lysis (dissolution or destruction) and soma 
(body)1. The lysosome has an essential function 
in the digestion of old organelles, engulfed 
proteins and microbes that are delivered to the 
lysosome for degradation by autophagy, 
endocytosis and phagocytosis, respectively. 
Delivery is mediated by kissing events between 
lysosomes and late endosomes/multivesicular 
bodies, or by direct fusion of lysosomes and 
autophagosomes2. Lysosomes can also fuse with 
the plasma membrane to mediate repair and 
exocytosis3. Sub-optimal lysosome function and 
reduced lysosomal clearance is associated with 
ageing, neurodegenerative diseases such as 
Alzheimer’s, and lysosomal storage disorders that 
are caused by deficiencies in lysosomal proteins 
or trafficking4. The lysosomal lumen harbours 
numerous acid hydrolases that digest a wide array 
of cellular macromolecules and membranes with 
the resulting catabolites being recycled back to 
the cytosol5. Lysosomal proteases have multiple 
additional roles, including bone remodelling, 
angiogenesis, neuronal cell maintenance, cell 
death and cancer cell invasion6. 
The lysosomal proteome has been 
investigated using a variety of mass spectrometry 
(MS)-based approaches, including affinity 
purification methods that exploit the mannose-6-
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phosphate modifications required to traffic 
proteins to the lysosome7–11. Such approaches 
have enabled the identification of both known and 
previously uncharacterised proteins involved in 
lysosome biology8. However, sorting signals 
present on lysosomal membrane proteins are less 
amenable to purification, and difficulties in 
isolating pure populations of lysosomes have 
hindered proteomic analysis of lysosomal 
membrane constituents. As a result, this proteome 
is considered relatively incomplete12. Traditional 
methods for isolating lysosomes have relied upon 
density centrifugation, resulting in preparations 
that are commonly contaminated by other 
organelles of similar density, including 
mitochondria and peroxisomes8,13–15. Protein 
correlation profiling can partially mitigate this 
problem and provide information about the 
steady-state distribution of proteins within 
organelles16,17. However, lysosomes can be highly 
heterogeneous in nature, and in biological 
contexts where their function is impaired or 
altered (e.g. in lysosomal storage disorders) 
changes in lysosomal buoyant density results in 
their redistribution across a density gradient, thus 
hampering their purification by differential 
centrifugation13,18,19. To overcome these 
difficulties, we and others have utilised magnetic 
iron nanoparticles to isolate lysosomes from 
different cell types13,18,20,21. Internalisation and 
delivery of nanoparticles via the endocytic 
pathway to lysosomes enables their isolation by 
magnetic chromatography. More recently, the 
utility of this method for LC-MS/MS analysis of 
cellular trafficking events has been 
demonstrated22,23. However, the application of 
this methodology to specifically investigate 
changes in the lysosomal membrane proteome in 
the context of lysosomal dysfunction (including 
during lysosomal membrane permeabilisation 
(LMP)) has yet to be explored. 
  Components of the lysosomal membrane 
fulfil a number of crucial functions, including 
acidification of the lysosomal lumen, membrane 
fusion with other organelles and transport events 
that facilitate the transfer of macromolecules and 
degradation products12,24. Preservation of 
lysosomal function requires the multicomponent 
vacuolar-type-ATPase to maintain the acidic 
luminal pH. The role of the densely glycosylated 
proteins LAMP1 and LAMP2, which constitute 
over 50% of the lysosomal membrane proteins12, 
is less clear. It has been suggested that they form 
a glycocalyx that protects the lysosomal 
membrane from autodigestion12,25. However, 
other studies indicate that they are not required 
simply for membrane stability12, although 
glycosylation is necessary to protect LAMP1/2 
from the action of lysosomal proteases25. LMP, 
and the subsequent intracellular release of 
lysosomal hydrolases such as cathepsin proteases, 
is widely implicated in the initiation or 
enhancement of cell death programmes26. Whilst 
cathepsin release may result in activation of the 
caspase cascade, cell death can also be initiated in 
a caspase-independent manner27 in a process 
termed lysosomal-mediated programmed cell 
death (LM-PCD)28. The mechanisms driving 
LMP appear to be highly cell type and context 
dependent, and have been observed across a wide 
spectrum of species including C. elegans29. In 
addition to mediating cell death in pathological 
conditions, LM-PCD can regulate cell death 
under physiological conditions, such as during 
post-lactational regression (involution) of the 
mammary gland20,30. This complex and highly 
regulated programme of cell death requires Stat3 
signalling that co-ordinately upregulates the 
lysosomal system and abrogates expression of the 
endogenous cathepsin inhibitor Spi2a30,31. 
Subsequent LMP and leakage of cathepsin 
proteases into the cytosol results in extensive cell 
death30. More recently, we have shown that Stat3 
activation mediates the uptake of milk fat 
globules that are delivered to large lysosomal 
vesicles for degradation20. The resulting high 
local concentrations of free fatty acids within 
these structures lead to increased membrane 
permeability, cathepsin leakage and cell death20. 
These events can be modelled in vitro using 
Oncostatin M (OSM) stimulation of Stat3 activity 
in the normal mouse mammary epithelial EpH4 
cell line20,30. It is unclear, however, if Stat3 
signalling has a direct, modulatory effect on the 
lysosomal membrane proteome. Here, we utilised 
LC-MS/MS analysis of lysosomes isolated from 
OSM-stimulated or unstimulated EpH4 cells to 
address this question, and to provide further 
insights into the protein composition of lysosomal 
membranes during LM-PCD.  
 
Results 
 
Iron nanoparticles facilitate the isolation of 
highly pure lysosomal preparations from 
EpH4 cells for mass-spectrometry analysis 
We previously developed a magnetic iron 
nanoparticle protocol to isolate functional 
lysosomes for membrane permeability studies20. 
To investigate the suitability of these preparations 
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for downstream MS analysis we sought to further 
characterise the lysosomes isolated using this 
method. By transmission electron microscopy 
(TEM) we observed that fluid phase uptake of 
nanoparticles by EpH4 cells led to the specific 
loading of degradative lysosomal vacuoles 
(Fig.1A). Importantly, these particles were non-
toxic, and cytotoxicity was only observed in the 
presence of hydrogen peroxide (Fig. 1B), likely a 
consequence of reactive free radicals generated 
by the Fenton reaction32. Using iron nanoparticles 
we were able to enrich and isolate EpH4 
lysosomes with relative ease (Fig. 1C). The 
lysosomal identity of the isolated organelles was 
confirmed by TEM analysis, which showed the 
presence of vacuolar structures containing 
magnetic nanoparticles (Fig. 1D, top panel). 
Furthermore, negative staining of samples also 
revealed the presence of iron-containing 
membrane bound organelles that were the size 
and morphology consistent with lysosomes (Fig. 
1D, lower panel). Importantly, fluorescence 
imaging and western blot analysis of iron-labelled 
(Mag+) preparations revealed near-undetectable 
levels of mitochondrial proteins (Fig. 1E and F), 
a common contaminant of lysosomal preparations 
isolated using methods such as density gradient 
centrifugation. In addition, contamination by 
other organelles, including endocytic vesicles and 
endoplasmic reticulum (ER), was minimal (Fig. 
1F), demonstrating the effectiveness of this 
method for yielding highly pure lysosomal 
preparations. 
To further enrich for lysosomal 
membrane proteins, and to reduce the 
contribution from cargo delivered to the 
lysosomes for degradation, isolated preparations 
were subjected to hypotonic lysis and 
centrifugation to separate lysosomal membranes. 
Using this method, the lysosomal membrane 
protein LAMP2 could be specifically detected in 
membrane fractions (LM, Fig. 2A). However, the 
lysosomal hydrolase cathepsin L (Ctsl) was 
detected at comparable levels in both membrane 
(LM) and soluble compartments (LC) of purified 
lysosomes (Fig. 2A and B), suggesting that not all 
organelles were successfully ruptured. To 
overcome this potential issue, preparations were 
subsequently subjected to repeat cycles of freeze-
thawing. This optimisation improved the 
enrichment of cathepsin activity in the soluble 
fraction (Fig. 2C), indicating the enhanced 
disruption of lysosomes. We also assessed the 
activity of β-glucuronidase, a lysosomal enzyme 
that is predominately localised in the lysosomal 
matrix and has minimal adherence to 
membranes33, to more definitively assess the 
degree of lysosomal membrane disruption. As 
expected, β-glucuronidase activity in the soluble 
fraction was higher than in membrane 
preparations, and was markedly increased by 
freeze thawing (Fig. 2D). Therefore, hypotonic 
lysis of isolated lysosomes, combined with freeze 
fracture, facilitated the enrichment of lysosomal 
membranes for downstream MS analysis. 
 
Mass-spectrometry analysis of EpH4 cell 
lysosomal membrane preparations isolated 
using iron nanoparticles 
To further validate and assess the 
efficacy of the optimised lysosomal membrane 
isolation procedure prior to undertaking large 
scale experiments, a pilot preparation was 
submitted for LC-MS/MS analysis. Here, 1664 
proteins were identified by MS (Supplementary 
Table S1A), which notably included numerous 
known lysosomal membrane proteins8,34 (Table 
1), thus validating the utility of our lysosomal 
purification method for downstream proteomic 
analysis. Proteins that were also identified in the 
corresponding unlabelled (no magnetic particles) 
control sample (327 proteins, Supplementary 
Table S1B), and that did not belong to the 
endocytic-lysosomal pathway, were removed 
from this list. Furthermore, published common 
contaminants of MS experiments35, such as heat 
shock proteins, keratins, tubulins, actins, 
elongation factors, histones, ribosomal and 
ribonucleo-proteins, were also removed. This 
resulted in a subset of 1295 proteins 
(Supplementary Table S2). To obtain a functional 
overview of the proteins identified, Kyoto 
Encyclopedia of Genes and Genomes (KEGG) 
pathway and Gene Ontology (GO) enrichment 
analysis was undertaken using the online gene list 
enrichment analysis tool, Enrichr36,37 
(http://amp.pharm.mssm.edu/Enrichr/). Analysis 
of the KEGG pathway annotations associated 
with this subset revealed a significant enrichment 
in proteins involved in lysosomal and related 
pathways, including neurodegenerative diseases 
allied with lysosomal dysfunction 
(Supplementary Fig. S1A and Supplementary 
Table S3A). Furthermore, GO term distribution 
analysis for Cellular Component (CC) confirmed 
the lysosomal and vesicular membrane 
localisation of the identified proteins 
(Supplementary Fig. S1B and Supplementary 
Table S3B). Functional analysis also revealed the 
enrichment of mitochondrial membrane proteins 
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involved in oxidative phosphorylation 
(Supplementary Fig. S1A and B). This suggests 
that lysosomal preparations isolated using iron 
nanoparticles may contain a degree of 
mitochondrial contamination that is undetectable 
by western blotting or MitoTrackerTM analysis 
(e.g. Fig. 1E, F). However, it is important to note 
that this contamination may also reflect the 
delivery of damaged mitochondria to the 
lysosome for turnover during mitophagy20,38, or 
the remnants of lysosome-mitochondrial contact 
sites39,40.  
 
Oncostatin M stimulates vesicle biogenesis in 
EpH4 cells 
We have previously shown that 
stimulation of EpH4 mammary epithelial cells by 
OSM leads to LMP30. OSM-induced Stat3 
phosphorylation in EpH4 cells resulted in the 
increased expression of multiple target genes, 
including the PI3Kinase subunits p55α and 
p50α41 and the lysosomal protease cathepsin B 
(Ctsb, Fig. 3A), alongside increased vacuole 
formation (Fig. 3B)20, which appeared to be 
degradative in nature (Fig. 3C). These structures 
accumulate the lysosomotropic dye 
LysoTracker® Red, thus revealing their lysosomal 
origin (Fig. 3D). Notably, the apparent size of the 
lysosomal compartment is increased by OSM 
treatment, and is associated with a more 
perinuclear localisation (Fig. 3D). 
To further characterise Stat3 induced 
changes to the lysosomal compartment, we 
sought to isolate lysosomes from OSM stimulated 
EpH4 cells using the optimised magnetic 
nanoparticle fractionation protocol. Western blot 
analysis of the lysosomal markers LAMP2 and 
cathepsin L (Ctsl) demonstrated that this 
technique was also applicable to OSM treated 
cells, and that the stimulation did not significantly 
interfere with iron uptake (Fig. 3E). Interestingly, 
OSM treatment resulted in increased LAMP2 
glycosylation, as observed by the molecular 
weight shift in LAMP2 on western blot (Fig. 3E). 
Prolonged OSM treatment resulted in cell death 
(Fig. 3B)30, leading to a reduction in protein 
yields as compared to control treated EpH4 cells 
(PNS lane in Fig. 3E). Despite this, OSM 
mediated induction of cathepsin L expression 
corresponded to an approximately sixteen-fold 
increase in enzyme activity inside the lysosomal 
matrix (LC, Fig. 3F).  
 
OSM induced changes to the EpH4 lysosomal 
proteome 
Having established that lysosomes from 
OSM treated EpH4 cells could be isolated using 
our purification method, we then investigated the 
effect of Stat3 activation on the lysosomal 
proteome. Lysosome membrane preparations 
from three independent biological replicates of 
vehicle and OSM treated cells were submitted for 
LC-MS/MS analysis. For each replicate a 
corresponding unlabelled (no iron particles) 
control was also included to filter out non-specific 
contaminants. Prior to MS analysis, lysosomes 
purified from OSM and control (vehicle) treated 
cells were assessed for lysosomal membrane 
enrichment (Fig. 4A) and purity (Fig. 4B). 
Importantly, western blot analysis of iron-
labelled lysosomal membrane (LM) preparations 
revealed near-undetectable levels of 
contamination by other organelles (Fig. 4B). 
However, we observed low levels of COX IV, a 
mitochondrial marker, in one of the three 
replicates (Fig. 4B), which was either derived 
from contaminating mitochondria or from 
lysosomal mitophagic cargo. A label-free, 
emPAI-based semi-quantitative proteomics 
approach was used to profile OSM induced 
changes in protein abundance (see methods). Raw 
data for all samples are shown in Supplementary 
Table S4. MS analysis of three independent 
biological repeats (three OSM and corresponding 
vehicle control samples) resulted in the 
identification of 35076 spectra within a 1% false 
discovery rate (0.66% decoy FDR), and an 
average spectrum identification rate of over 24% 
(Supplementary Table S5). Coalescence of 
redundant identifications from repeat and 
overlapping peptides resulted in a list of 644 
unique proteins at a probability of over 99%, 
which contained at least 3 identified peptides 
(established at greater than 95% probability), 
within a false discovery rate of less than 5% (Fig. 
4C, Supplementary Tables S4 and S6). Proteins 
that were also identified in the corresponding 
unlabelled (no magnetic particles) control sample 
for each independent replicate, and not belonging 
to the endocytic-lysosomal pathway, were 
removed from this list. In addition, known 
common contaminants35 were deleted as before. 
Exceptions to this rule were considered if their 
representations changed significantly with OSM 
treatment; e.g. Keratin 8, which is a definitive 
marker of luminal mammary epithelial cells. This 
resulted in a subset of 447 proteins (Fig. 4C and 
Supplementary Table S7). 320 out of 447 were 
identified in at least 5 of the 6 preparations (3 x 
vehicle, 3 x OSM treated samples) 
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(Supplementary Table S8). Pathway analysis 
(KEGG, 2016) on this more stringent subset 
validated the lysosomal nature of the proteins 
identified, which included numerous known 
lysosomal components (Fig. 4D and 
Supplementary Table S9A). A significant 
enrichment was also observed for components 
involved in phagocytosis. This is not unexpected 
given the ultimate destination of phagosomes is 
the lysosomal compartment. Moreover, GO term 
distribution analysis for Cellular Component 
(CC) confirmed the lysosomal and vesicular 
membrane localisation of the identified proteins 
(Fig. 4E and Supplementary Table S9B). In 
vehicle and OSM treated samples, three and 21 
proteins were exclusively identified, respectively 
(Fig. 4C, Table 2).  
Whilst the lysosomal nature of most 
proteins (408/447) remained similar between 
vehicle and OSM treated preparations, a subset of 
39 proteins (~ 9%) showed more significant 
changes in abundance between the different 
conditions (Fig. 4C, Table 3 and Supplementary 
Table S10). A striking decrease in lysosomal 
enzymes, including galactocerebrosidase, beta-
hexosaminidase and lysosomal alpha-
mannosidase was observed with OSM treatment 
(Fig. 4F, Table 3 and Supplementary Table S10), 
suggesting either that Stat3 affects the 
distribution of these enzymes or, more likely, that 
these have been depleted from the lysosomes as a 
result of LMP. OSM stimulation also resulted in 
the increased representation of cell surface 
proteins and cytoskeletal components such as 
integrins, annexins and flotillins (Fig. 4F, Table 3 
and Supplementary Table S10). Interestingly, this 
suggests that endocytosis, and the subsequent 
transport and localisation of cargo into the 
lysosomal compartment, is stimulated upon Stat3 
activation, supporting our previous observations 
in vivo20. 
In order to validate these results, 
immunoblot analysis of lysosomal protein 
preparations, used for the MS analysis, was 
undertaken. Flotillins are interesting candidates 
as they are involved in endocytosis and 
membrane trafficking, and form clusters in 
plasma membrane lipid rafts42,43.  Flotillin 1 was 
significantly enriched in lysosomes isolated from 
OSM stimulated cells (Fig. 4F, Table 3) and 
whilst not statistically significant, the related 
protein flotillin 2 also showed an increased 
representation in OSM treated lysosomes (Fig. 
4F). While flotillin 1 and flotillin 2 were 
undetectable in lysosomal preparations from 
untreated EpH4 cells, OSM stimulation of Stat3 
activity resulted in the appearance of considerable 
amounts of both these proteins in the lysosomal 
compartment (Fig. 5A). This is not surprising as 
flotillin 2 has previously been observed to traffic 
from the plasma membrane to endosomes42,43, 
which may subsequently fuse with lysosomal 
structures. Further support for the endocytosis of 
flotillins in response to Stat3 is provided by the 
observation that OSM treatment of EpH4 cells for 
only 24h resulted in increased internalisation of 
flotillin 2 puncta in EpH4 cells (Supplementary 
Fig. S2).   
Annexins A1, A6 and A11 were also 
enriched in lysosomal fractions following OSM 
stimulation (Table 3). Our previous microarray 
data of a mammary gland developmental cycle44 
revealed the downregulation of these annexins 
during lactation (Supplementary Fig. S3). 
Interestingly, while expression levels of annexin 
A6 remained fairly consistent across all lactation 
and involution timepoints, a substantial increase 
in the expression of annexins A11 and A1 was 
observed during involution (Supplementary Fig. 
S3). This pattern is similar to that of flotillins 1 
and 2 (Fig. 5B) suggesting that all these 
membrane proteins may play significant roles in 
regression of the mammary gland. Indeed, mRNA 
expression of both Flot1 and Flot2 is 
downregulated approximately 2-fold in the 
mammary glands of Stat3 knock-out mice at 24 h 
involution (Supplementary Table S11). In 
addition, the glutathione–S-transferase Mgst1 
was also identified in lysosomal preparations 
purified from OSM-treated EpH4 cells (Tables 2 
and 3). Mgst1 is a de-toxifying enzyme and 
therefore may be upregulated in response to iron 
nanoparticle uptake. However, as it is only 
present in the OSM treated samples, it is tempting 
to speculate that it could be induced to protect 
against the effects of LMP. Indeed, an increase in 
Mgst1 and the related protein Mgst3 is observed 
during mammary gland involution 
(Supplementary Fig. S3), suggesting that they 
may possess important functions during 
lysosomal-mediated cell death in vivo. 
Whilst a significant number of known 
lysosomal membrane proteins were identified by 
MS analysis, the relative yield of some peptides 
(including from abundant proteins such as 
LAMP1 and 2) was lower than expected, 
similarly to that observed in previous studies34. 
One possible explanation is that the heavily 
glycosylated nature of many lysosomal 
membrane proteins may interfere with MS 
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analysis. To address this possibility, lysosomal 
membrane samples were deglycosylated using 
Peptide-N-Glycosidase F (PNGase F) prior to 
proteomic analysis. PNGase F is an amidase that 
cleaves between the innermost N-
Acetylglucosamine (GlcNAc) and asparagine 
residues of oligosaccharides from N-linked 
glycoproteins45. PNGase F treatment resulted in 
the efficient removal of N-linked glycans from 
LAMP2 proteins, as shown by the appearance of 
a sharp band at approximately 30 kDa by 
immunoblot analysis (Supplementary Fig. S4). 
To determine whether the representation of 
heavily glycosylated proteins is improved after 
deglycosylation, PNGase F-enzyme treated and 
untreated lysosomal membrane samples were 
analysed by LC-MS/MS. Western blot analysis of 
various organelle markers was performed to 
check the purity of the preparations as described 
before (Supplementary Fig. S4). 955 and 718 
proteins were identified in control and enzyme-
treated lysosomal membrane samples 
respectively (Supplementary Table S12). 
Comparative analysis of heavily glycosylated 
proteins, such as LAMP1, LAMP2, LIMP2 and 
CD63/LIMP1, revealed that deglycosylation 
increased the number of unique peptide 
sequences identified for these proteins, vastly 
improving their representation and identification 
by LC-MS/MS (Supplementary Table S13). Of 
note, deglycosylation did not appear to have a 
detrimental impact on the identification of 
lysosomal membrane proteins, with the majority 
higher ranked in PNGase F-treated samples 
(Supplementary Table S13). Therefore, future 
proteomic experiments investigating lysosomal 
membrane composition will likely benefit from 
utilising deglycosylating approaches prior to LC-
MS/MS. 
 
Stat3 mediated regulation of the lysosomal 
compartment 
To investigate the biological relevance of 
OSM-induced changes to the lysosomal 
compartment, we used CRISPR/Cas9 technology 
to ablate Stat3 in EpH4 cells. Mass spectrometry 
analysis revealed that the lysosomal membrane 
protein LAMP2 is upregulated in response to 
OSM stimulation of Stat3 activity (Fig. 4F, Table 
3). Indeed, LAMP2 and LAMP1 immunostaining 
in EpH4 cells clearly showed enhanced lysosomal 
biogenesis in response to OSM, with lysosomes 
becoming increasingly perinuclear in distribution 
(Fig. 5C). Surprisingly, we found that deletion of 
Stat3 abrogated the increase in apparent 
molecular weight of LAMP1 and LAMP2 that 
occurs in response to OSM treatment (Figs. 3E 
and 5D) suggesting a role for this post-translation 
modification of LAMP1 and LAMP2 in lysosome 
function. Importantly, a similar shift in mobility 
is observed during involution of the mouse 
mammary gland30, and is likely due to a change 
in glycosylation. Stat3 also upregulates 
expression of the lysosomal protease cathepsin B 
and the endo-lysosomal membrane protein, CD63 
(Fig. 5D and Supplementary Table S11). At a 
transcriptional level, both CD63 
and Lamp2 mRNAs are downregulated during 
lactation, and rise sharply during involution 
(Fig. 5E). Together, these data suggest that 
Stat3 directly modulates lysosomal membrane 
constituents to induce lysosomal leakiness and 
consequent cell death.  
 
Discussion 
The lysosome is enjoying a renaissance 
as a signalling centre and monitor of cellular 
nutritional status46. While microarray studies are 
very useful in highlighting transcriptional 
changes in response to transcription factors such 
as Stat3, these are of little value in determining 
the functional downstream consequences of 
altered protein expression. Having determined a 
role for Stat3 in lysosomal function, we aimed to 
characterise this at the level of the lysosomal 
membrane proteome in order to shed further light 
on the mechanism of LMP in mammary epithelial 
cells. 
In the past decade, an increased 
knowledge of the lysosomal proteome has been 
acquired through the application of MS8,14,22,34. 
However, although numerous lysosomal 
membrane proteins have so far been identified 
using density centrifugation14,34, these data do not 
fully correlate with the plethora of known and 
crucial functions of the lysosomal membrane and 
its constituent proteins and enzymes. This failure 
to detect all lysosomal membrane proteins, 
coupled with the contamination inherent in 
lysosome enrichment approaches used to date, 
prompted us to develop an alternative method to 
enrich lysosomal membrane proteins. In order to 
circumvent alterations in the size or buoyant 
density of lysosomes in response to changes in 
cellular status, we utilised a different approach 
that is independent of these features. Labelling 
and subsequent isolation of lysosomes by uptake 
of magnetic nanoparticles resulted in highly pure 
lysosomal membrane preparations being 
obtained. Although proteins that reside in other 
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organelles were not detected by immunoblotting 
and MitoTrackerTM analysis, a number of 
mitochondrial and other organellar proteins were 
detected by MS. Although this could be due to 
contamination, we suggest it is more likely the 
consequence of autophagy, which we have 
previously shown to be induced in EpH4 cells, 
particularly in response to OSM38. Indeed, we 
observed a considerable number of degradative 
structures present even in control, non-OSM 
stimulated cells (Fig. 3)20. Functional analysis of 
our MS data corroborated the lysosomal nature of 
the samples, and provided valuable insights into 
membrane trafficking events as well as lysosomal 
function. Importantly, although heavily 
glycosylated proteins such as LAMP1, LAMP2, 
CD63/LIMP1 and LIMP2 were detected, they 
were relatively underrepresented. This is likely 
due to glycosylation-mediated changes in mass 
and therefore the time of flight, which has an 
impact on the resolution of the peptide spectrum 
acquired47. We show that prior deglycosylation 
treatment considerably improves the 
representation of these proteins (Supplementary 
Table S13), and suggest that future proteomics 
experiments should consider utilising this 
approach. 
  We analysed the lysosomal proteome in 
both intact and leaky lysosomes, the latter treated 
with OSM to induce Stat3 activation and 
subsequent LMP. Interestingly, OSM treatment 
resulted in a clear loss of lysosomal enzymes, 
probably as a consequence of LMP and leakage 
of proteases to the cytosol. In contrast, OSM 
induced elevated levels of cargo probably as a 
consequence of increased endocytosis and 
downregulation of cell surface receptors and 
adhesion complexes that are subsequently 
delivered to the lysosome. Observed changes in 
cytoskeletal proteins may be relevant to 
lysosomal localisation, which in turn influences 
internal pH48 with possible effects on protease 
functions and LMP. In support of this notion, 
OSM stimulation intriguingly resulted in 
increased perinuclear distribution of lysosomes in 
EpH4 cells (Figs. 3D and 5C). 
Interesting candidates for further 
characterisation include flotillins 1 and 2. Data 
from this study show that OSM treatment causes 
trafficking of these proteins to the degradative 
endo-lysosomal pathway. Flotillins (or reggies) 
form clusters in lipid rafts, and have been shown 
to regulate trafficking of α5 and β1 integrins and 
thus the formation of focal adhesions49. We 
speculate that OSM treatment induces cells to 
detach with consequent turnover of focal 
adhesions and trafficking of integrins to the 
lysosome. Indeed, mRNA expression of both 
Flot1 and Flot2 is downregulated approximately 
2-fold in the mammary glands of Stat3 knock-out 
mice at 24 h involution (Supplementary Table 
S11). Their roles in regulating mammary cell 
death during involution in vivo, therefore, 
warrants further investigation. 
Other interesting candidates for 
validation include annexins A1 (Anxa1), A6 
(Anxa6) and A11 (Anxa11). Annexins are a 
family of highly conserved proteins that bind to 
negatively charged phospholipids and 
membranes in a calcium dependent manner50. 
Studies in annexin knockout mice have suggested 
that annexin-A1 fulfils multiple roles, including 
trafficking at the plasma membrane and in the 
endocytic compartment50. Annexin-A6 is also 
involved in membrane organisation and the 
distribution of proteins in rafts51. Recently, 
annexin-A11 has been shown to physically 
associate with a component of the coat protein 
complex II (COPII) machinery that is associated 
with the ER and controls transport of 
transmembrane cargoes from the ER to the 
Golgi52. Thus, the changes we have observed in 
lysosomal levels of these three annexins could be 
a reflection of the elevated vesicle formation 
induced by OSM.  
Finally, using CRISPR/Cas9 technology 
to ablate Stat3 in EpH4 cells, we reveal a direct 
role for Stat3 signalling in the regulation of 
lysosomal proteins such as cathepsin B, CD63, 
LAMP1 and LAMP2. Surprisingly, we show that 
Stat3 regulates the glycosylation status of 
LAMP1 and LAMP2 in response to OSM 
treatment in EpH4 cells (Fig. 5D), mimicking that 
observed during involution of the mouse 
mammary gland30. An intriguing possibility is 
that Stat3 could induce expression of 
fucosyltransferases in mammary epithelial cells, 
since LIF/Stat3 has been shown to regulate 
expression of alpha1,2-fucosyltransferases FUT1 
and FUT2, which transfer fucoses onto the 
terminal galactose of N-acetyl-lactosamine53. It 
has been shown recently that FUT1 regulates the 
subcellular localisation of lysosomes, with FUT1 
knockdown inducing perinuclear accumulation54, 
similar to that observed upon OSM stimulation 
(Figs. 3D and 5C). Together, our data suggest that 
Stat3 activation induces endocytosis of plasma 
membrane constituents (including flotillins and 
annexins) that consequently results in a dramatic 
increase in endo-lysosomal trafficking, and the 
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subsequent enhancement of the lysosomal 
system. 
In summary, this study has refined the 
utility of magnetic iron nanoparticles for the 
isolation of highly pure lysosomal membrane 
preparations for downstream proteomic analysis. 
Notably, this method can be applied to purify 
leaky lysosomes undergoing membrane 
permeabilisation, revealing valuable insights into 
the cellular trafficking events that may contribute 
to Stat3-mediated cell death. Vacuolisation is 
implicated in driving cell death in a variety of 
organisms, including plant55 and Dictyostelium 
discoideum56 cells. Intriguingly, an activated 
form of the H-Ras oncoprotein was recently 
reported to induce extensive vacuolisation and 
subsequent cell death in cultured cancer cells57. 
Thus, our method may be utilised more widely to 
investigate the lysosomal proteome in contexts 
associated with lysosomal perturbations, such as 
cancer, neurodegenerative diseases and 
lysosomal storage disorders. An improved 
understanding of the mechanisms driving 
lysosomal membrane permeabilisation is pivotal 
for developing new and effective therapies 
against the many disorders associated with 
aberrant lysosomal function.  
 
Experimental procedures 
 
Cell Culture 
EpH4 cells58 were maintained in DMEM 
(Life Technologies) media supplemented with 
10% FCS (Sigma) at 37 °C in a humidified 
atmosphere of 5% CO2. For OSM stimulation, 
cells were stimulated at 50% confluency with a 
final concentration of 25 ng ml−1 recombinant 
mouse oncostatin M (495-MO, R&D Systems) or 
carrier (0.0001% BSA in PBS) in DMEM 
supplemented with 1% FCS. Medium was 
renewed with fresh OSM (in 1% FCS/DMEM) 
after 48 h. Cells were harvested 72 h after 
stimulation.  Cytotoxicity was assessed by trypan 
blue exclusion. 
 
CRISPR/Cas9 Stat3 KO cell line generation 
Two SpCas9 guide sequences targeting 
the mouse Stat3 gene were designed using the 
sgRNA scoring algorithm from Doench and 
colleagues59. These were cloned into the 
lentiCRISPRv2 plasmid, lentivirus was produced, 
EpH4 cells were transduced and puromycin 
selected according to previously described 
protocols60,61. Using these, two independent 
Stat3KO lines were derived and maintained in the 
pooled state (as single cell cloning of EpH4 cells 
would likely lead to clonal artefacts). Stat3KO1 
was created from virus expressing the guide 
sequence GTACAGCGACAGCTTCCCCA, and 
Stat3KO2 from virus expressing the guide 
sequence GGAACTGCCGCAGCTCCATG. As 
these two lines use different guide sequences, 
they act as off-target controls for one another and 
so any phenotypes observed can be attributed to 
the loss of Stat3. Deletion of Stat3 was confirmed 
by TIDE analysis62 and western blotting. To 
further control for any effects of lentiviral 
transduction and SpCas9 expression, virus 
expressing a ‘scrambled’ guide 
(AAATTAAATTTAATTTAAAG) that does not 
target any mouse coding sequences was also used.  
 
Ferrofluid labelling and purification of 
lysosomes 
Lysosomes from EpH4 cells were 
purified using magnetic iron nanoparticles 
(EMG-508, Ferrotec) as previously described20. 
Briefly, EpH4 cells were seeded at a density of 
3×106, or 1x106 for OSM stimulation, in 15 cm 
tissue culture plates (168381, Nunc). The 
following day, or after 48 h of OSM stimulation, 
cells were labelled for 4 h in iron nanoparticle 
containing media (EMG series 508, FerroTec, 
1:100) followed by a 20 h chase period in clean 
media (including fresh OSM in the case of 
stimulation experiments). Cells were then scraped 
in PBS, pelleted in a table-top centrifuge (300 
r.p.m., 4°C, 3 min) and the pellet homogenised in 
a tight-fitting handheld homogenizer (5 strokes) 
in 700 μl subcellular fractionation buffer 
(HEPES-KOH 20 mM, sucrose 250 mM, KCl 10 
mM, MgCl2 1.5 mM, EDTA 1 mM, EGTA 1 mM, 
dithiothreitol 8 mM, Complete protease inhibitor 
(Roche) at pH 7.5). The homogenate was spun at 
750 g (3,500 r.p.m., 4°C, 10 min) to remove 
nuclei and other debris, followed by a second 750 
g spin to ensure complete removal of 
contaminating heavy membranes. The resulting 
supernatant (PNS; post nuclear supernatant) was 
transferred into a clean tube, loaded onto a 
magnetic rack and incubated for 1 h at 4°C on a 
rocker. A 50 μl sample of PNS was retained for 
analysis. Following incubation tubes were left on 
the magnet and the supernatant (SN) removed 
(retaining 50 μl for analysis). Tubes were washed 
three times with 1 ml of subcellular fraction 
buffer. Following addition of the last wash tubes 
were removed from the magnet, and spun at 
12,000 r.p.m. (13,800 g, 4°C, 15 min) to pellet 
magnetite-containing lysosomes. To limit 
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contamination by proteins non-specifically 
sticking to the eppendorf pellets were 
resuspended and combined in a final volume of 
200 µl fractionation buffer and transferred into a 
clean eppendorf. The samples were then pelleted 
at 13,800 g for a further 15 min at 4 °C, along with 
the PNS and SN samples.  
 
Fractionation of purified lysosomes 
To obtain “total” lysosomal lysates, 
whole lysosomes purified as described above 
were incubated with 0.1% Triton X-100 (VWR) 
for 10 min on ice, intermittently vortexed four 
times and spun at 12,000 r.p.m (13,800 g, 4°C)) 
for 15 min. The supernatant was transferred into 
new tubes. To separate the lysosomal content 
from the lysosomal membrane fraction, the 
isolated lysosomes were resuspended in 5 mM 
Tris buffer pH 7.5, incubated on ice for 30 min or 
frozen in liquid nitrogen, and thawed at 37°C five 
times. Lysosomal membranes were pelleted by 
spinning at 15,000 g for 30 min at 4°C. The 
supernatant (lysosomal content, LC) was 
transferred into a new tube. The pellet was 
resuspended in 50 µl 0.1% Triton X-100 in PBS, 
incubated 10 min on ice and intermittently 
vortexed four times. After spinning at 17,000 g 
for 10 min at 4°C the supernatant (lysosomal 
membrane fraction, LM) was transferred into 
fresh tubes. 
  
Immunoblotting 
PNS and SN samples were pelleted and 
resuspended in 50 µl modified RIPA buffer (50 
mM Tris, 1% NP40, 0.25% sodium deoxycholate, 
150 mM NaCl, 1 mM EGTA and complete 
protease inhibitor), and lysed on ice for 30 min 
with intermittent vortexing. Samples were then 
spun at 12,000 r.p.m. (13,800 g, 4°C, 15 min) and 
the supernatant retained for western blotting 
analysis. Protein samples (made up in modified 
RIPA buffer, 0.1% Triton X-100 or 5 mM Tris as 
described above) were denatured and resolved on 
SDS–polyacrylamide gels. Proteins were 
separated by SDS-PAGE under reducing 
conditions unless otherwise stated.  
Immunoblotting was performed using standard 
techniques and antibody detection was achieved 
with enhanced chemiluminescence reagent (ECL, 
GE Healthcare). The following primary 
antibodies were used: rat anti-LAMP2 (ab13524, 
Abcam, 1:1,000), goat anti-cathepsin L (AF1515, 
R&D Systems, 1:1,000), goat anti-cathepsin B 
(AF965, R&D Systems, 1:1,000), mouse anti-
COX IV (ab33985, Abcam, 1:1,000), rabbit anti-
PI3 Kinase, p85 (06-496, Millipore, 1:1000), 
rabbit anti-Stat3 (sc-482, Santa Cruz, 1:1000), 
rabbit anti-phospho Stat3 (9131, Cell Signaling, 
1:1000), mouse anti-ERp57 (sc-23886, Santa 
Cruz, 1:400), rabbit anti-GAPDH (5174, Cell 
Signaling, 1:1000), goat anti-histone H3 (sc-
8654, Santa Cruz, 1:1000), rabbit anti-Rab5 
(2143, Cell Signaling, 1:1000), rat anti-LAMP1 
(ID4B, Developmental Studies Hybridoma Bank 
1:200), rat anti-CD63 (NVG-2 #143901 
Biolegend, 1:1000), rabbit anti-flotillin 1 (#18634 
Cell Signaling Technology 1:800) and rabbit anti-
flotillin 2 (HPA0013961, Atlas Antibodies 
1:200). All horseradish peroxidase (HRP)-
conjugated secondary antibodies were from 
Dako. 
 
Cathepsin Activity Assay 
10 μl of lysates were added to a total of 
200 μl cathepsin reaction buffer (sodium acetate 
50 mM, EDTA 8 mM, dithiothreitol 8 mM and 
Pefabloc subcellular fractionation buffer 1 mM, 
at pH 6). Cathepsin B and L activity was 
measured with the fluorescent substrate Z-Phe-
Arg-AMC (50 μM; Merk Millipore) in a Synergy 
HT Multi-Detection Microplate Reader 
(excitation 380 nM, emission 442 nM; Bio-TEK). 
Fluorescence was measured immediately every 
minute for 1 h at 37°C. Initial rates of cathepsin 
B and L activity were determined from the linear 
part of the resulting curve and normalized to total 
cathepsin activity obtained from Triton X-100-
extracted lysates. Cathepsin activity reaction 
buffer alone or containing 50 µM z-F-R-AMC 
served as controls. The assay was performed in 
duplicate or triplicate per condition in a 96-well 
flat bottom microtitre plate (Thermo Scientific). 
 
β-glucuronidase Assay 
10 μl of lysates were added to 125 µl of 
Sodium Acetate/Acetic Acid Buffer (0.1 M 
sodium acetate, 0.1 M acetic acid, pH 4.8) 
containing 10 mM of the fluorescent substrate 4-
Methylumbelliferone-β-D-glucuronide (4-MU-
Glu, Biosynth) on ice. Samples were incubated 
for 30 min at 37°C, and the reaction subsequently 
stopped by the addition of 100 µl 
Glycine/Carbonate Buffer (0.17 M glycine, 0.17 
M sodium carbonate, pH 9.8) on ice. 
Fluorescence was measured in a Synergy HT 
Multi-Detection Microplate Reader (excitation 
380 nM, emission 442 nM; Bio-TEK). Sodium 
Acetate/Acetic Acid Buffer alone or containing 
10 mM 4-MU-Glu served as controls. The assay 
was performed in duplicate or triplicate per 
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condition in a 96-well flat bottom microtitre plate 
(Thermo Scientific). 
 
FITC dextran and mitotracker staining of 
lysosomal preparations 
EpH4 cells were seeded at a density of 
3x106 in 15 cm Nunc cell culture dishes (Thermo 
Scientific). Plates were either labelled for 2 h with 
2.5 mg/ml 10 kDa FITC-dextran (Sigma) in 10% 
DMEM containing 10% Ferrofluid in BSA/PBS 
(+) or in FITC-dextran containing media only 
(minus iron nanoparticles (-)). Cells were washed 
three times in PBS followed by a 2 h chase period 
in 10% DMEM, prior to labelling of mitochondria 
with 500 nM Mitotracker (MitoTracker Red FM, 
Invitrogen) in 10% DMEM for 30 min. Plates 
were then washed three times in PBS and the cells 
scraped into 500 μl PBS and spun at 900 g for 3 
min at 4°C. Cell pellets were resuspended in 700 
µl fractionation buffer containing complete 
protease inhibitors and homogenised with five 
strokes in a dounce homogenizer. To obtain the 
PNS the homogenate was spun at 800 g for 10 
min at 4°C. The PNS was transferred into a new 
tube and 50 µl retained for analysis (PNS -/+). 
The PNS was incubated on a magnetic rack for 1 
h at 4°C on a rocker. Post incubation the 
supernatant (SN) was removed and 50 µl kept for 
analysis (SN -/+). The tubes were washed three 
times with 1 ml cold fractionation buffer on the 
magnetic rack. Following the last wash, the tubes 
were removed and spun at 13,800 g for 15 min at 
4°C. The lysosomal pellet (LP -/+) was 
resuspended in 25 μl fractionation buffer. 10 μl of 
the magnetic nanoparticle labelled and unlabelled 
PNS, SN, and lysosomal pellets were mixed with 
10 μl PBS/glycerol (v/v 50:50) and dropped onto 
a microscope slide and covered by a cover slip for 
imaging using a Zeiss Axioplan 2 microscope and 
a Plan-APOCHROMAT 63x/1,4 oil objective 
(Zeiss). 
 
Immunofluorescence and LysoTracker Red 
staining 
EpH4 cells were seeded on glass 
coverslips or ibidi 35mm glass bottom dishes and 
stimulated with OSM as described above the 
following day. After OSM stimulation cells were 
fixed with 4% paraformaldehyde for 5 min at 
37oC and subsequently permeabilized with 0.5% 
v/v TritonX-100 in PBS for 10 min at room 
temperature. Cells were blocked in 10% normal 
goat serum (Sigma) in PBS for 1 h at room 
temperature and then incubated with primary 
antibody in PBS for 1 h at room temperature, or 
overnight at 4°C. Primary antibodies used were 
rat anti-LAMP2 (GL2A7 #ab13524, Abcam 
1:200), rat anti-LAMP1 (ID4B, Developmental 
Studies Hybridoma Bank 1:200) and rabbit anti-
flotillin 2 (HPA0013961, Atlas Antibodies 
1:200). Cells were then washed in PBS followed 
by secondary antibody staining (Cy3 goat anti-rat 
IgG, Life Technologies, 1:500; Alexa Fluor 488 
goat anti-rabbit IgG, Invitrogen A11008, 1:500; 
or Alexa Fluor 647 goat anti-rat IgG, Life 
Technologies A21247, 1:500) for 1 h at room 
temperature. Nuclei were counterstained with 
Hoechst 33342 (Sigma Aldrich; 1:1000). Cells 
were stained with LysoTracker Red DND-99 
(Life Technologies) at 1:10,000 for 30 min at 
room temperature according to manufacturer’s 
instructions. Images were acquired using a Zeiss 
Axioplan 2 microscope (Zeiss, Jena, Germany) or 
a Leica TCS SP8 inverted confocal microscope. 
Image reconstructions were generated ImageJ 
(v1.50c, National Institutes of Health)63. 
 
Transmission election microscopy (TEM) 
EpH4 cell lysosomes were isolated using 
the magnetic nanoparticle protocol and adsorbed 
to a TEM grid. This was followed by two wash 
steps in H2O to remove any remaining buffer 
salts. Samples were either directly imaged using 
a Tecnai G2 electron microscope or negatively 
stained with 1% uranyl acetate beforehand.  
 
Silver staining of protein gels 
Protein samples were run on 4-15% 
Mini-Protean TGX Gels (BioRad) and fixed in 
45% methanol, 1% v/v in ddH2O for 30 min. 
After washing in ddH2O the gels were sensitized 
with 0.02% sodium thiosulfate (Na2S2O3) for 1 
min and rinsed in ddH2O three times for 20 sec. 
Afterwards the gels were stained in ddH2O 
containing 0.2% silver nitrate (AgNO3) and 
0.02% Formaldehyde for 20 min. This was 
followed by rinsing two times in ddH2O for 20 sec 
and developing for 3 min in 3% sodium carbonate 
(Na2CO3), 0.0005% sodium thiosulfate, 0.05% 
Formaldehyde in ddH2O. The developed gels 
were rinsed two times in ddH2O for 20 sec and 
blocked in 5% Acetic Acid. 
 
Mass-spectrometry methods 
All MS experiments were undertaken at 
the Cambridge Centre for Proteomics (University 
of Cambridge). For all experiments submitted for 
MS analysis, a corresponding unlabelled (no 
magnetic particles) control sample was also 
analysed. For the OSM-related experiments, three 
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independent biological repeats (three OSM and 
corresponding vehicle control samples) were 
performed, and a corresponding unlabelled (no 
magnetic particles) control sample also submitted 
for each independent replicate. 
 
Silver destaining and tryptic digest 
After 1D gel electrophoresis, gel pieces 
were cut into 1-2 mm cubes and placed into 0.5 
ml tubes. The gel pieces were incubated with 100 
µl silver destaining solution (a 1:1 ratio of 27 mM 
potassium ferricyanide (K3[Fe(CN)6]) and 100 
mM sodium thiosulphate (Na2S2O3)  in high 
performance liquid chromatography (HPLC) 
grade water) for 10 min at 37°C. This step was 
repeated with fresh destaining solution until 
complete clarification of the gel pieces. 
Subsequently, pieces were washed in HPLC 
grade water, prior to incubation in 100% 
acetonitrile at 37°C until they appeared white and 
shrunken. The acetonitrile was removed and any 
residual solution evaporated by incubating at 
37°C for 10 min. To reduce the proteins, the gel 
pieces were incubated in 50 µl 10 mM DTT made 
up in 100 mM ammonium bicarbonate 
(NH4HCO3) at 56°C for 1 h. For alkylation 50 µl 
55 mM iodoacetamide (C2H4INO) made up in 
100 mM ammonium bicarbonate was then added, 
and incubated at room temperature in the dark for 
45 min. The liquid was removed and 100 µl 100 
mM ammonium bicarbonate added and incubated 
at 37°C for 10 min. After removing the liquid, the 
gel pieces were incubated in 50% acetonitrile 
(C2H3N) in 100 mM ammonium bicarbonate at 
37°C for 10 min, which was then replaced by 100 
µl 100% acetonitrile to dry the gel pieces. To 
evaporate the acetonitrile, the gel pieces were 
incubated further at 37°C, to ensure that they were 
completely dry prior to tryptic digest. 50-60 µl of 
trypsin solution (10 ng/µl in 50 mM ammonium 
bicarbonate) was added to the gel pieces and 
incubated overnight. 
 
LC-MS/MS analysis 
After tryptic digestion, the supernatant 
was pipetted into a sample vial and loaded onto 
an autosampler for automated LC-MS/MS 
analysis. The pilot LC-MS/MS experiment was 
performed using a Dionex Ultimate 3000 RSLC 
nanoUPLC (Thermo Fisher Scientific Inc, 
Waltham, MA, USA) system and a QExactive 
Orbitrap mass spectrometer (Thermo Fisher 
Scientific Inc, Waltham, MA, USA). All OSM-
related and deglycosylation experiments were 
performed using a Waters NanoAcquity UPLC 
(Thermo Fisher Scientific Inc, Waltham, MA, 
USA) system and an Orbitrap Velos mass 
spectrometer (Thermo Fisher Scientific Inc, 
Waltham, MA, USA). For the pilot experiment 
using the Q Exactive, separation of peptides was 
performed by reverse-phase chromatography at a 
flow rate of 300 nL/min and a reverse-phase nano 
Easy-spray column (Thermo Scientific PepMap 
C18, 2 µm particle size, 100 Å pore size, 75 µm 
i.d. x 50 cm length). Peptides were loaded onto a 
pre-column (Thermo Scientific PepMap 100 C18, 
5 µm particle size, 100 Å pore size, 300 µm i.d. x 
5mm length) from the Ultimate 3000 autosampler 
with 0.1% formic acid for 3 min at a flow rate of 
10 µL/min. After this period, the column valve 
was switched to allow elution of peptides from 
the pre-column onto the analytical column. 
Solvent A was water + 0.1% formic acid and 
solvent B was 80% acetonitrile, 20% water + 
0.1% formic acid. The linear gradient employed 
was 2-40% B in 30 min. The LC eluant was 
sprayed into the mass spectrometer by means of 
an Easy-spray source (Thermo Fisher Scientific 
Inc.). All m/z values of eluting ions were 
measured in an Orbitrap mass analyzer, set at a 
resolution of 70000. Data dependent scans (Top 
20) were employed to automatically isolate and 
generate fragment ions by higher energy 
collisional dissociation (HCD) in the quadrupole 
mass analyser and measurement of the resulting 
fragment ions was performed in the Orbitrap 
analyser, set at a resolution of 17500. Peptide ions 
with charge states of 2+ and above were selected 
for fragmentation.  
For the nanoAcquity/Orbitrap Velos 
experiments, separation of peptides was 
performed by reverse-phase chromatography 
using a Waters reverse-phase nano column (BEH 
at flow rate of 300 nL/min. Peptides were initially 
loaded onto a pre-column (Waters UPLC Trap 
particle size) from the nanoAcquity sample 
manager with 0.1% formic acid for 3 minutes at a 
column valve was switched to allow the elution 
of peptides from the pre-column onto the 
analytical column. Solvent A was water + 0.1% 
formic acid and solvent B was acetonitrile + 0.1% 
formic acid. The linear gradient employed was 3-
40% B in 40 minutes (60 minutes total run time 
including wash and equilibration steps). 
The LC eluant was sprayed into the mass 
spectrometer by means of a standard Thermo 
Scientific nanospray source. All m/z values of 
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eluting ions were measured in the Orbitrap Velos 
mass analyzer, set at a resolution of 30000. Data 
dependent scans (Top 20) were employed to 
automatically isolate and generate fragment ions 
by collision-induced dissociation in the linear ion 
trap, resulting in the generation of MS/MS 
spectra. Ions with charge states of 2+ and above 
were selected for fragmentation. Post-run, all data 
were processed using Protein Discoverer (version 
2.1., ThermoFisher). 
All LC-MS/MS data generated from the 
pilot and deglycosylation experiments were 
converted to mgf files and these files were then 
submitted to the Mascot search algorithm (Matrix 
Science, London UK) and searched against the 
Uniprot mouse database (UniProt_Mouse_Oct13 
10090_Oct2013 82208 sequences; 36313543 
residues) using a fixed modification of 
carbamidomethyl (C) and variable modifications 
of oxidation (M) and deamidation (NQ). Peptide 
identifications were accepted if they could be 
established at greater than 95.0% probability.  
For analysis of OSM-related experiments data all 
MS/MS data were converted to mgf files and 
submitted to the Mascot search algorithm (Matrix 
Science, London UK) and searched against the 
swissprot_2013_11 database (with a mouse 
taxonomy filter, 16693 sequences). Mascot was 
searched with a fragment ion mass tolerance of 
0.80 Da and a parent ion tolerance of 25 PPM. 
Trypsin was specified as the enzyme and 
carbamidomethyl of cysteine was specified in 
Mascot as a fixed modification. Deamidation of 
asparagine and glutamine and oxidation of 
methionine were specified in Mascot as variable 
modifications. For protein identification, Scaffold 
(version Scaffold_4.7.2, Proteome Software Inc., 
Portland, OR) was used to validate MS/MS based 
peptide and protein identifications. Peptide 
identifications were accepted if they could be 
established at greater than 95.0% probability by 
the Scaffold Local FDR algorithm. Protein 
identifications were accepted if they could be 
established at greater than 99.0% probability to 
achieve an FDR less than 5.0% and contained at 
least 3 identified peptides. Protein probabilities 
were assigned by the Protein Prophet algorithm64. 
Proteins that contained similar peptides and could 
not be differentiated based on MS/MS analysis 
alone were grouped to satisfy the principles of 
parsimony. To estimate OSM induced changes in 
protein abundance, the 
Exponentially Modified Protein Abundance Inde
x (emPAI) values of OSM and vehicle treated 
samples were compared65. emPAI provides an 
approximate and relative quantitation of the 
proteins in a mixture based on protein coverage 
by the peptide matches in a database search result. 
This method takes into account the fact that more 
observed peptides will be generated for larger 
proteins, and for proteins that have many peptides 
in the preferred mass range for mass 
spectrometry65. Whilst emPAI and other similar 
spectral counting methods provide only semi-
quantitative information, they are highly 
correlative to protein abundance65. EmPAI values 
were calculated in Scaffold version 4.7.2, in 
addition to all comparative analysis of OSM and 
vehicle treated samples and associated statistics. 
 
Deglycosylation of lysosomal proteins 
1 μl 10x Glycoprotein Denaturating 
Buffer (New England Biolabs) was added to 9 μl 
of lysosomal membrane proteins. The 
glycoproteins were denatured by heating to 95°C 
for 10 min. Subsequently, 2 μl 10x G7 Reaction 
Buffer (New England Biolabs), 2 μl 10% NP 40 
(New England Biolabs) and 1 μl Peptide -N-
Glycosidase F (PNGaseF, New England Biolabs) 
were added and the reaction volume made up to 
20 μl with H2O. The reaction mix was incubated 
at 37°C for 30 min. The deglycosylated protein 
samples were used for MS or made up in 4x 
sample buffer and analysed by western blot. 
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Table 1: Known lysosomal membrane proteins identified in lysosomal preparations isolated using 
iron nanoparticles 
Published lysosomal membrane proteins identified by mass spectrometry in a preliminary experiment 
to validate the iron nanoparticle-mediated lysosomal isolation protocol. Associated with Supplementary 
Table S1. 
 
Protein Reference Protein Reference 
H+-ATPase V1 subunit A 
Schröder,B et 
al34 
LIMP2 Reczek, D. et al66 
H+-ATPase V1 subunit B2 Schröder, B. et al34 Sialin Miyaji, T. et al67 
H+-ATPase Vo 116kDa subunit a 
isoform 1 
Schröder, B. et al34 CLC-7 Lange, P. F. et al68 
H+-ATPase Vo subunit d Schröder, B. et al34 ATPase 13A2 Schmidt, K. et al69 
H+-ATPase V1 56/58-kDa subunit 
B1 
Schröder, B. et al34 Mucolipin-1 Zeevi, D. A. et al70 
H+-ATPase V1 subunit H splice 
isoform 1 
Schröder, B. et al34 rPHT2 Sakata, K. et al71 
H+-ATPase V1 subunit C Schröder, B. et al34 GLUT-8 Schmidt, S. et al72 
H+-ATPase V1 subunit E Schröder, B. et al34 
Equilibrative 
nucleoside transporter 
3 
Baldwin, S. A. et 
al73 
H+-ATPase Vo 116kDa subunit a 
isoform 2 
Schröder, B. et al34 
Natural resistance-
associated 
macrophage protein 2 
Tabuchi, M. et al74 
H+-ATPase V1 subunit Da Schröder, B. et al34 Zinc transporter 2 
Falcón-Pérez, J.M. 
et al75 
H+-ATPase V1 subunit G1 Schröder, B. et al34 
ATP-binding cassette 
subfamily A member 3 
Chapuy, B. et al76 
S1 accessory proteins (Ac45) Schröder, B. et al34 
ATP-binding cassette 
subfamily B member 9 
Demirel, O. et al77 
H+-ATPase Vo 16-kDa proteolipid 
subunit c 
Schröder, B. et al34 
Probable lysosomal 
cobalamin transport 
Rutsch, F. et al78 
Glucosylceramidase Schröder, B. et al34 
Major facilitator 
superfamily domain-
containing protein 8 
Siintola, E. et al79 
Arf-like 10C (Arl8B) Schröder, B. et al34 
Heparan-α-
glucosaminide N-
acetyltransferase 
Fan, X. et al80 
Flotillin 1 Schröder, B. et al34 
Signal peptide 
peptidase-like 2A 
Friedmann, E. et 
al81 
Arf-like 10B (Arl8A) Schröder, B. et al34 Nicastrin 
Pasternak, S. H. et 
al82 
Lysosomal α-glucosidase Schröder, B. et al34 Presenilin1 
Pasternak, S. H. et 
al82 
SLC29A3 nucleoside transporter Schröder, B. et al34 
Transmembrane 
protein 55A 
Ungewickell, A. et 
al83 
Chloride Channel 5, CLC5 Schröder, B. et al34 
Transmembrane 
protein 55B 
Ungewickell, A. et 
al83 
MLN64 N-terminal domain 
homolog 
Schröder, B. et al34 
Vesicle-associated 
membrane protein 7 
Pryor, P. R. et al84 
Phospholipase D1 isoform, PLD1A Schröder, B. et al34 
Transmembrane 
protein 192 
Schröder, B. et al34 
Endothelin-converting enzyme 1 
isoform B 
Schröder, B. et al34 
Lysosomal protein 
NCU-G1 
Schieweck, O. et 
al85 
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C18orf8 protein, Mic1 Schröder, B. et al34 
Transmembrane 
protein 63A 
Schröder, B. A. et 
al8 
SID1 transmembrane protein, 
SIDT2 
Schröder, B. et al34 
Niemann-Pick C1 
protein 
Chen, F.W. et al86 
GPR137 protein Schröder, B. et al34 
Niemann-Pick C2 
protein 
Chikh, K. et al87 
LAMP1 Eskelinen, E-L. et al88 
Osteopetrosis-
associated 
transmembrane 
protein 1 
Lange, P. F. et al68 
LAMP2 Eskelinen, E-L. et al88   
CD63/LIMP1 Schröder, J. et al89   
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Table 2. Proteins identified by MS in control (vehicle) or OSM treated lysosomal preparations 
only 
Associated with Figure 4 and Supplementary tables S4, S6 and S7.  
 Accession Gene symbol Protein Name 
V
eh
ic
le
 o
n
ly
 Q8VDV8 Mitd1 MIT domain-containing protein 1 
Q9WVE8 Pacsin2 Protein kinase C and casein kinase substrate 
in neurons protein 2  
Q8BHL4 Gprc5a Retinoic acid-induced protein 3  
O
S
M
 o
n
ly
 
Q80X90 Flnb Filamin-B 
Q9EPR5 Sorcs2 VPS10 domain-containing receptor SorCS2 
Q8BKG3 Ptk7 Inactive tyrosine-protein kinase 7 
P40124 Cap1 Adenylyl cyclase-associated protein 1  
Q91V01 Lpcat3 Lysophospholipid acyltransferase 5  
P48678 Lmna Prelamin-A/C  
Q61738 Itga7 Integrin alpha-7  
Q91V92 Acly ATP-citrate synthase  
Q91VS7 Mgst1 Microsomal glutathione S-transferase 1  
Q8BU30 Iars Isoleucine--tRNA ligase, cytoplasmic  
O70309 Itgb5 Integrin beta-5  
Q80VQ0 Aldh3b1 Aldehyde dehydrogenase family 3 member 
B1  
P35821 Ptpn1 Tyrosine-protein phosphatase non-receptor 
type 1  
O70133 Dhx9 ATP-dependent RNA helicase A  
Q9DBG3 Ap2b1 AP-2 complex subunit beta  
P14901 Hmox1 Heme oxygenase 1  
Q6P9J9 Ano6 Anoctamin-6  
Q8BTM8 Flna Filamin-A 
Q61739 Itga6 Integrin alpha-6 
P97384 Anxa11 Annexin A11  
Q62261 Sptbn1 Spectrin beta chain, non-erythrocytic 1  
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Table 3. Proteins that were differentially represented in OSM treated lysosomal preparations. 
16 (pink) and 23 (blue) proteins were differentially represented in control and OSM treated samples 
respectively (depicted in Fig. 4C). Many lysosomal enzymes were decreased by OSM, whilst the 
lysosomal localisation of cell surface and cytoskeletal components were increased. Proteins that were 
absent/near absent from the comparator sample (INF or 0) are not plotted in Fig. 4F. 
Name Symbol 
Accession 
Number 
p-value (T-
TEST) 
Fold Change: 
OSM/veh 
(emPAI) 
MIT domain-containing protein 1 OS Mitd1 Q8VDV8 0.034 0 
Epoxide hydrolase 1 OS Ephx1 Q9D379 0.015 0.06 
Galactocerebrosidase OS Galc P54818 0.0021 0.09 
Palmitoyl-protein thioesterase 1 OS Ppt1 O88531 0.00089 0.1 
Acid ceramidase OS Asah1 Q9WV54 0.014 0.1 
E3 ubiquitin-protein ligase RNF13 OS Rnf13 O54965 0.043 0.1 
CD82 antigen OS Cd82 P40237 0.0091 0.2 
Beta-hexosaminidase subunit beta OS Hexb P20060 0.022 0.2 
Lysosomal alpha-mannosidase OS Man2b1 O09159 0.014 0.3 
IST1 homolog OS Ist1 Q9CX00 0.019 0.3 
Beta-glucuronidase OS Gusb P12265 0.047 0.3 
Lactadherin OS Mfge8 P21956 0.0067 0.4 
Ras-related protein Rab-18 OS Rab18 P35293 0.025 0.4 
Claudin-3 OS Cldn3 Q9Z0G9 0.011 0.5 
Retinoid-inducible serine 
carboxypeptidase OS 
Scpep1 Q920A5 0.014 0.5 
Sideroflexin-1 OS Sfxn1 Q99JR1 0.046 0.5 
Lysosome-associated membrane 
glycoprotein 2 OS 
Lamp2 P17047 0.003 1.5 
Integrin beta-1 OS Itgb1 P09055 0.017 2.2 
Monocarboxylate transporter 1 OS Slc16a1 P53986 0.022 2.5 
Basigin OS Bsg P18572 0.0017 3.1 
Importin subunit beta-1 OS Kpnb1 P70168 0.0026 3.5 
Annexin A1 OS Anxa1 P10107 0.0051 4.3 
ADP-ribosyl cyclase 2 OS Bst1 Q64277 0.022 4.5 
Catenin delta-1 OS Ctnnd1 P30999 0.013 4.9 
Annexin A6 OS Anxa6 P14824 0.0025 5.8 
Junction plakoglobin OS Jup Q02257 0.023 8.1 
Talin-1 OS Tln1 P26039 0.032 8.5 
Flotillin-1 OS Flot1 O08917 0.036 8.7 
Keratin, type II cytoskeletal 8 OS Krt8 P11679 0.0016 9.3 
T-complex protein 1 subunit beta OS Cct2 P80314 0.018 9.6 
Vinculin OS Vcl Q64727 0.027 12 
Protein-glutamine gamma-
glutamyltransferase 2 OS 
Tgm2 P21981 0.044 14 
Microsomal glutathione S-transferase 
1 OS 
Mgst1 Q91VS7 0.0049 INF 
Filamin-A OS Flna Q8BTM8 0.0056 INF 
Integrin alpha-6 OS Itga6 Q61739 0.027 INF 
Annexin A11 OS Anxa11 P97384 0.028 INF 
Filamin-B OS Flnb Q80X90 0.041 INF 
Integrin alpha-7 OS Itga7 Q61738 0.041 INF 
Inactive tyrosine-protein kinase 7 OS Ptk7 Q8BKG3 0.042 INF 
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Figure legends 
 
Figure 1. Iron nanoparticle mediated isolation of EpH4 cell lysosomes.  
A, Transmission electron microscopy (TEM) of EpH4 cells showing iron nanoparticles residing in 
degradative lysosomal vacuoles (arrow head) or in lysosomal vacuoles devoid of degradative material 
(arrow). Scale bars: 500 nm. B, Brightfield microscopy and quantification of iron nanoparticle-induced 
cell death of EpH4 cells, observed solely in the presence of hydrogen peroxide (H2O2). EpH4 cells were 
treated with H2O2 for 19 h. Scale bars: 25 μm. C, Schematic of the magnetic iron nanoparticle lysosomal 
purification protocol. Adapted from Sargeant, Lloyd-Lewis et al, 201420. D, TEM of lysosomes (top 
panel) and of negatively stained lysosomes (bottom panel) isolated using the magnetic iron nanoparticle 
purification protocol. Arrowheads mark areas containing iron nanoparticles. Arrows indicate 
unidentifiable membranous fragments, which may be endo-lysosomal tubules or remnants from the ER 
or Golgi apparatus. Scale bars: 500 nm. E, Isolated EpH4 lysosomes are predominantly clear of 
mitochondria. EpH4 cells were labelled with 10 kDa FITC-dextran (2.5 mg/ml, green) with (Mag +) or 
without (Mag -) iron nanoparticle containing media for 2 h and subsequently stained with 
MitoTrackerTM (500 nm, red) for 30 min prior to isolation. Representative images of the post nuclear 
supernatant (PNS), post magnetic supernatant (SN) and of the magnetic lysosomal pellet (LP) of the 
two conditions are shown. Scale bar: 10μm. F, Isolated EpH4 lysosomes are highly pure with 
undetectable contamination from other organelles as observed by immunoblotting. N, nuclear lysate. 
Organelle marker proteins: LAMP2, lysosomes; ERp57, endoplasmic reticulum; GAPDH, cytoplasm; 
Rab5, early endosomes; Cox IV, mitochondria; Histone H3, nucleus.   
 
Figure 2. Membrane fractionation of isolated EpH4 lysosomes.  
A, Hypotonic lysis of iron nanoparticle isolated lysosomes from EpH4 cells to separate the lysosomal 
membranes (LM) from the lysosomal content (LC). LAMP2 immunoblotting shows its enrichment in 
the LM fraction. Ctsl, cathepsin L (single chain: sc; double chain: dc); PNS, post nuclear supernatant; 
SN, post magnetic supernatant. B, Cathepsin activity in EpH4 lysosomes isolated using iron 
nanoparticles and extracted using TX-100 (total lysosomal content, TX+) or by hypotonic lysis and 
fractionation (membrane fractions: LM+, matrix: LC+) compared to unlabelled control samples (TX-, 
LM- and LC-).  C, D, Freeze thawing of lysosomes improved lysosome membrane separation from the 
lysosomal matrix. Cathepsin (C) and -glucuronidase activity (D) in the LC fraction is shown as a fold 
of LM. 
 
Figure 3. OSM induces vesicular biogenesis in EpH4 cells.  
A, Immunoblot showing OSM induced expression of p55α/p50α and cathepsin B (Ctsb; sc, single chain) 
downstream of activated Stat3 signalling in EpH4 cells. B, Brightfield microscopy showing OSM 
induced vacuolisation in EpH4 cells treated for 72 h. Scale bars: 25 μm. C, TEM images showing an 
increased number of degradative vesicles after 72 h of OSM stimulation. Scale bars: 500 nm. D, 
Fluorescence microscopy of LysoTracker® accumulation in cells treated with OSM for 72 h. Scale bars: 
20 μm. E, Western blot analysis of LAMP2 and cathepsin L in fractionated lysosomes isolated from 
vehicle and OSM stimulated (72 h) cells using iron nanoparticles. Post nuclear supernatant (PNS), 
lysosomal membrane fraction (LM), single chain cathepsin L (sc Ctsl), heavy chain of the double-chain 
form of cathepsin L (dc Ctsl). F, Graph showing increased cathepsin activity in LC and LM fractions 
from OSM stimulated cells.  
 
Figure 4. OSM induced changes in the lysosomal proteome of EpH4 cells.  
A, Western blot analysis of LAMP2 and cathepsin L in fractionated lysosomes isolated from vehicle 
and OSM stimulated (72 h) cells and submitted for MS analysis. A representative blot from three 
independent experiments is presented. Post nuclear supernatant (PNS), lysosomal content fraction (LC), 
lysosomal membrane fraction (LM), single chain cathepsin L (sc Ctsl), heavy chain of the double-chain 
form of cathepsin L (hc Ctsl).  B, Immunoblotting for organelle marker proteins in lysosomal 
preparations isolated from control and OSM stimulated EpH4 cells. ERp57, endoplasmic reticulum; 
GAPDH, cytoplasm; Rab5, early endosomes; Cox IV, mitochondria; Histone H3, nucleus. A 
representative blot from three independent experiments is presented. For Cox IV immunoblotting, blots 
from two different replicates are shown, revealing slight contamination in one replicate. C, Analysis 
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pipeline of mass spectrometry results obtained from lysosomes isolated from vehicle and OSM (72 h) 
treated EpH4 cells. 3 independent biological repeats were undertaken per condition, and each replicate 
included an unlabeled control samples (9 preparations in total). D, Significantly enriched KEGG (2016) 
pathways derived from MS analysis of EpH4 lysosomal preparations isolated using iron nanoparticles. 
E, Significant GO annotations of proteins according to cellular component, derived from mass-
spectrometry analysis of EpH4 lysosomal preparations isolated using iron nanoparticles. For inclusion 
in the analysis undertaken in D and E, proteins were required to be identified in at least 5 out of 6 
independent runs (3 veh, 3 OSM). F, Volcano plot showing the fold change in emPAI values induced 
by OSM stimulation. Proteins that were significantly changed by OSM treatment are shown in green 
(T-Test, p < 0.05) 
 
Figure 5. Stat3 mediated regulation of the lysosomal compartment 
A, Western blot validation of the lysosomal localisation of flotillin 1 and flotillin 2 in iron nanoparticle 
isolated EpH4 lysosomes (Mag+) after 72 h OSM stimulation. Post nuclear supernatant (PNS). White 
asterix indicates the expected molecular weight of flotillin 2. Representative blots of n=3 (flotillin 1) 
and n=2 (flotillin 2) independent experiments are shown. B, Microarray analysis of twelve different 
timepoints during the mammary gland pregnancy cycle showing the involution related expression 
profiles of flotillin 1 and flotillin 2. V, virgin; d G, days gestation; d L, days lactation; h I, hours 
involution. C, Fluorescence microscopy of LAMP1 and LAMP2 immunostaining in EpH4 cells treated 
with OSM for 72 h. Scale bars: 10 μm. D, Western blot analysis of OSM induced changes to the 
lysosomal proteins LAMP1, LAMP2, CD63, and cathepsin B in whole cell lysates from normal (WT) 
and two independent Stat3 KO EpH4 cell lines after 72 h of stimulation. Proteins were separated by 
SDS-PAGE under reducing or non-reducing conditions as indicated. Pro form of cathepsin B (pro-
Ctsb), single chain cathepsin B (sc Ctsb), scrambled sgRNA control EpH4 cells (Scram). E, Microarray 
analysis of twelve different timepoints during the mammary gland pregnancy cycle showing the 
involution related expression profiles of CD63 and LAMP2. 
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